An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R/R) LBCL.

This document provides information about a clinical trial in China for the treatment of relapsed or refractory large B-cell lymphoma (LBCL). The trial is studying the use of a biological treatment called Relma-cel, which involves the administration of CAR+T cells. The study aims to evaluate the effectiveness, safety, and pharmacokinetics of Relma-cel in LBCL patients. The trial is currently in the interventional phase and is expected to be completed by April 2025. [Extracted from the article]